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authors’ reply We thank Dr. Satoh et al for their 
interest in our manuscript and for their insight‑
ful comments. Below we respond to all questions 
listed in their letter.
First, we completely agree that the lavaged 
lobe(s) should have been identified in the Meth‑
ods section. Indeed, in all subjects with suspect‑
ed interstitial lung disease, including controls, 
the right middle lobe/lingula was lavaged. How‑
ever, in patients with lung cancer, bronchoalveolar 
lavage (BAL) was always performed in the direct 
vicinity of the tumor. Consequently, there were 
4 patients lavaged in the right upper lobe; 3, in 
the right middle lobe; 2, in the right lower lobe; 
5, in the left upper lobe, and 2, in the lingual. We 
are very sorry for this oversight.
Second, as the authors correctly emphasized, 
our study group included only nonsmoking pa‑
tients with idiopathic pulmonary fibrosis (IPF). 
This was clearly mentioned in the Patients and 
methods and Results sections. Therefore, our re‑
sults and conclusions refer to this group only 
To the editor With great interest, we read the ar‑
ticle by Kopiński et al1 on increased levels of in‑
terleukin 27 (IL ‑27) in patients with early clini‑
cal stages of non–small cell lung cancer. We would 
like to ask several questions. First, the authors 
described that the middle lobe of the right lung 
(or alternatively the lingual of the left lung) was 
lavaged. On the other hand, they described that 
bronchoalveolar lavage (BAL) was performed as 
part of a routine diagnostic workup of a periph‑
eral solitary pulmonary lesion. We would like to 
know whether patients with lung cancer had the 
primary lesion in the middle lobe or the lingual 
of the left lung, or perhaps a different site than 
the middle lobe was lavaged? Second, idiopathic 
pulmonary fibrosis (IPF) is a disease with a pos‑
sible association with smoking,2 and IL ‑27 levels 
in this study were measured only in nonsmoking 
patients with IPF.1 We would like to know wheth‑
er this was appropriate as data representative of 
patients with IPF. Third, what is the clinical sig‑
nificance of high levels of IL ‑27 in BAL fluid? Did 
high IL ‑27 levels have pathological meanings, not 
through the bloodstream but via the respiratory 
tract? Do the high levels of IL ‑27 have the same 
pathological significance in lung cancer and non‑
malignant respiratory diseases? Fourth, it is in‑
teresting that the range of high and low IL ‑27 lev‑
els in BAL fluid was broad in patients with lung 
cancer. What is the authors’ opinion on this? Is 
there a possibility that angiogenesis was patho‑
logically extensive in lung cancer patients with 
high IL‑27 levels in BAL fluid?
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stimulate T cells, significantly promoting efficient 
mycobacteria elimination. Likewise, Ye et al14 sug‑
gested that pleura ‑derived IL ‑27 affects mesothe‑
lial cells inducing their proliferation and stimu‑
lating local wound healing processes.
A number of in vivo studies have provided data 
on the IL ‑27/WSX ‑1 axis involvement in bron‑
chial asthma. WSX ‑1–deficient mice with exper‑
imentally induced asthma demonstrated airway 
hyperresponsiveness, increased lung eosinophil 
migration, and overproduction of immunoglobu‑
lin, as compared with control animals with normal 
IL ‑27 receptor signalling. Th2 ‑related cytokine 
secretion in WSX ‑1–deficient mice was also in‑
creased. It was suggested that IL ‑27 exerts an in‑
hibitory effect on Th2 cells and therefore might 
protect against asthma.15 On the other hand, IL‑
‑27 is implicated in airway hyperresponsiveness 
in patients with severe asthma. IL ‑27 synergizes 
with IFN ‑γ, affecting directly lung macrophages 
in a MyD88 ‑dependent mechanism.16 Addition‑
ally, it was demonstrated that respiratory syn‑
cytial virus‑induced asthma exacerbation could 
be suppressed by neutralizing IL ‑27 and IFN ‑γ.17
In chronic obstructive pulmonary disease 
(COPD), Cao et al18 observed the elevated IL‑
‑27 levels in the airways and implicated a num‑
ber of cellular subsets as its source. Also, a nega‑
tive correlation between IL ‑27 concentrations in 
sputum and FEV1 seems to confirm its impact on 
COPD severity. According to Qiu et al,19 high IL‑
‑27 expression in COPD is associated with both 
Th1 and Th17 cell activity, while its neutralization 
improves the clinical course of disease. IL ‑27 was 
also shown to induce the CXCL10 expression on 
lung fibroblasts and epithelial cells and therefore 
promote immune cell migration into the sites of 
inflammation, lymphoid follicle formation, and 
steroid resistance.18,20,21 In secondary bacterial 
pneumonia and acute respiratory distress syn‑
drome (ARDS), IL ‑27 levels negatively correlate 
with clinical outcome.22 In ARDS, the ability of 
IL ‑27 to induce and intensify the inflammatory 
response seems particularly deteriorating,23 while 
its deficit favors severe lung inflammation in ex‑
perimental animals.24 It has also been suggested 
that high IL ‑27 levels suppress IL ‑17 and increase 
susceptibility to bacterial pneumonia, as exem‑
plified by a significantly increased risk of second‑
ary respiratory infections (Staphylococcus aureus, 
Streptococcus pneumoniae) in the course of influ‑
enza.25,26 In conclusion, we strongly believe that 
the biological effect of IL ‑27 is very much con‑
text dependent.
Finally, Dr Satoh et al very precisely indicated 
the wide range of IL ‑27 concentrations in BAL 
fluid from patients with NSCLC. This observa‑
tion should not be surprising as, per definition, 
NSCLC is a rather heterogeneous group of lung 
cancers. Moreover, cytological, immunological, 
and biochemical variables of BAL fluid generally 
show non–Gaussian distribution. Relative neu‑
trophil and eosinophil counts in BAL fluid are 
characterized by Poisson distribution, unlike in 
and are in no way representative of smokers with 
IPF. IPF is indeed more common in smokers. Yet, 
paradoxically bronchoalveolar lavage (BAL) flu‑
id is difficult to obtain in this subgroup, as many 
smokers with IPF have contraindications to BAL. 
An overlap between the deleterious impact of 
smoking (as reflected by reduced forced expira‑
tory volume in 1 second [FEV1]) and other respi‑
ratory pathologies (eg, hypoxia due to IPF) pre‑
cludes BAL in a number of patients with IPF. Low 
or unsatisfactory lavage representativeness (eg, 
BAL fluid recovery <30% of instilled volume, ep‑
ithelial cell contamination >5%, etc) for the low‑
er airways should also be considered.1-3 Finally, 
we assessed interleukin (IL)‑27 concentrations in 
BAL fluid, but from 2 smokers with IPF (15.7 and 
0 pg/ml in BAL supernatant) only. This number is 
too low to allow any conclusions or comparisons.
Third, our opinion on the role of IL ‑27 in local 
immunity in non–small cell lung cancer (NSCLC) 
and ILD, was presented in the manuscript, though 
briefly due to word count limits. As indicated in 
the literature, IL ‑27 plays an important role in 
maintaining respiratory system homeostasis. Due 
to its versatile effect, particularly on T ‑lympho‑
cyte subsets, macrophages, and airway epithelial 
cells, it regulates numerous pathological process‑
es within the respiratory tract. It has been shown 
that IL ‑27 expression significantly affects, not 
necessarily in a positive way, the clinical course 
of tuberculosis, atopic bronchial asthma, chron‑
ic obstructive pulmonary disease, malignancies, 
and other inflammatory reactions in the lungs.
Some authors suggested a significant negative 
effect of IL ‑27 on immune response against My-
cobacterium tuberculosis.4-6 In WSX ‑1–deficient 
subjects with impaired IL ‑27–dependent signal‑
ing, mycobacteria are more susceptible to pha‑
golysosomal fusion in macrophages and are elim‑
inated relatively fast.7,8 Holscher et al9 proved 
that mycobacteria elimination from infected mac‑
rophages in WSX ‑1–deficient subjects depends 
on increased secretion of proinflammatory cy‑
tokines—tumor necrosis factor (TNF) and IL‑
‑12p40 subunits—with subsequent Th ‑dependent 
interferon‑γ (IFN ‑γ) production. In fact, they 
demonstrated the bidirectional activity of IL‑
‑27 in active tuberculosis: the WSX ‑1/IL ‑27 axis 
limits the immune reaction in tuberculosis and 
facilitates bacilli survival, and on the other hand, 
IL ‑27 reduces TNF and IL ‑12 release by activated 
macrophages and prevents extensive inflamma‑
tory response.4,9 Another possible mechanism, 
namely, secretion of IL ‑10 in CD4+ T cells,  has 
been shown by Moreira ‑Teixeira et al.10 More‑
over, in tuberculosis‑infected macrophages, IL‑
‑27 inhibits lysosomal acidification and phagoly‑
sosomal function (affecting numerous proteins: 
CD63, V ‑ATPase, and cathepsin D). As a result, 
IL ‑27 might support prolonged mycobacteria sur‑
vival in macrophage ‑immature lysosomes.5,11,12
Yet, changes in local IL ‑27 concentrations sig‑
nificantly affect the spectrum of its biological ef‑
fects: Zhang et al13 showed that high IL ‑27 levels 
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peripheral blood.27-30 This is in line with our data 
demonstrating a wide range of IL ‑27 concentra‑
tions in BAL fluid, some below the lower limit 
of detection.
A surprising observation that we were unable 
to adequately explain and therefore did not in‑
clude it in the original manuscript is that alve‑
olar lymphocytes positive for intracellular IL‑
‑27 were found in BAL fluid from all study partic‑
ipants, while no IL ‑27+ lymphocytes in peripher‑
al blood were ever observed. We believe that this 
finding provides yet another argument for the 
concept that BAL lymphocytes are indeed a lo‑
cal source of IL ‑27.
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